Baxter's commitment to haemostatic and tissue sealing agents spans more than 30 years and more than 15 million surgeries. Today, the company continues its quest for advancing BioSurgery by offering a comprehensive line of biological and synthetic products for haemostasis, sealing and adhesion reduction based on the latest scientific advances in the field.